Murano Announces Enhancements to its Core Strategy with Bitcoin (BTC) Treasury Initiative Following Execution of Up to $500 Million Standby Equity Purchase Agreement (SEPA) - Murano Global Investments (NASDAQ:MRNO), Murano Global Investments (NASDAQ:MRNOW)

Murano Global Investments (NASDAQ:MRNO) shares rose 70.52% after hours following a Nasdaq compliance extension and strategic review announcement. The company has until April 5, 2027, to meet the $1.00 minimum bid price rule. Murano is exploring options to boost shareholder value, including a potential data center in Mexico. The company also reported mixed hotel performance and ongoing debt restructuring efforts. Shares closed at $0.24 on Wednesday.

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, raising its price target to $4.00. The company reported positive Phase 1 and Phase 2 results for RP-A501 in Danon disease, with FDA alignment on pivotal trial design. Rocket secured a $150M credit facility to fund operations until Q3 2028. Analysts have mixed views on the stock's potential.

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.